Status:
COMPLETED
Expand New Drugs for TB [endTB]
Lead Sponsor:
Partners in Health
Collaborating Sponsors:
Médecins Sans Frontières, France
Interactive Research and Development
Conditions:
Tuberculosis, Multidrug-Resistant
Eligibility:
All Genders
Brief Summary
This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gat...
Eligibility Criteria
Inclusion
- Any patient who receives a treatment regimen containing bedaquiline or delamanid at an endTB site will be invited to participate in this observational study, regardless of age or gender.
- Any patient who signs the study informed consent form will be included in the study.
Exclusion
- Refusal to participate in the study.
Key Trial Info
Start Date :
April 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
2804 Patients enrolled
Trial Details
Trial ID
NCT03259269
Start Date
April 1 2015
End Date
December 30 2019
Last Update
June 13 2022
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
National Treatment Centre for Tuberculosis, Abovian, Armenia
Abovyan, Armenia
2
National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka
Dhaka, Bangladesh
3
Republican Research and Practical Centre for Pulmonology and Tuberculosis
Minsk, Belarus, 220053
4
Aung San Tuberculosis Hospital
Yangon, Burma